The Mesenchymal-Epithelial Transition Factor (MET) Market represents a revolutionary segment within precision cancer care, driven by pioneering discoveries in MET pathway dysregulation and the development of highly targeted therapeutic agents. These treatments primarily focus on MET-altered non-small cell lung cancer (NSCLC), particularly malignancies harboring MET exon 14 skipping...